Coronavirus Disease 2019 (COVID-19) – Pipeline and Clinical Trial Analysis – June 2020
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Over the coming months, as trial data readouts become available, frontrunners will emerge in both the therapeutic and preventive categories. Currently, the therapeutics space is dominated by candidates already approved for other disease indications; one of these products, an IL-6 inhibitor already marketed for an immunology indication, is well positioned to win the first regulatory approval for COVID-19. The number of clinical trial delays has been steadily increasing throughout Q1 and into Q2 2020. As activity begins to pick up later in the year, trial sponsors might strive to make up for lost time, but the extensive delays will be difficult to overcome entirely.
Scope
Profiles of the most promising treatments and vaccines in the pipeline for COVID-19, including SWOT analyses, an overview of trials, and summaries of available data
An overview of the clinical trials landscape, including discussion of the approaches being adopted for therapeutic and vaccine development
Highlights in deal-making trends, particularly public-private partnerships
Proprietary expert insights on COVID-19 R&D obtained by GlobalData's investigative journalism team
Analysis of the impact of the outbreak on clinical trial timelines across disease areas and geographies
Assessment of regulatory delays associated with the pandemic
GlobalData poll results on topics covered in the report
Reasons to Buy
Stay abreast of COVID-19 R&D
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.